NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors.

Michael Cecchini Zenta Walther Wei Wei Navid Hafez Mary Jo Pilat Scott A Boerner Diane E Durecki Joseph Paul Eder Kurt A Schalper Helen X Chen Patricia M LoRusso

Published in: Cancer research communications (2023)

The combination of intermittent veliparib with weekly irinotecan was deemed too toxic for further development. Future PARPi combinations should focus on agents with nonoverlapping toxicities to improve tolerability. The treatment combination showed limited efficacy with prolonged stable disease observed in multiple heavily pretreated patients, but no objective responses were seen.

Keyphrases

end stage renal disease
open label
ejection fraction
newly diagnosed
high intensity
chronic kidney disease
prognostic factors
high dose
randomized controlled trial
current status
placebo controlled
replacement therapy
double blind